Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoliang Shi

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Oncology Reports|April 3, 2020
Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non‑small cell lung cancerJing Hu, Yanhong Shang, Xiaoliang Shi, et al.
Frontiers in Oncology|June 27, 2022
A Comprehensive Understanding of the Genomic Bone Tumor Landscape: A Multicenter Prospective StudyXianbiao Xie, Yiying Bian, Haomiao Li, et al.
Translational Oncology|May 6, 2024
The FGF6 amplification mutation plays an important role in the progression and treatment of malignant meningiomaRuihao Liang, Binhua Tan, Kai Lei, et al.
The EMBO Journal|June 9, 2020
Myeloid cells protect intestinal epithelial barrier integrity through the angiogenin/plexin-B2 axisRongpan Bai, Desen Sun, Muxiong Chen, et al.
Scientific Reports|November 21, 2020
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinibYanhong Shang, Xiaofang Li, Weiwei Liu, et al.
International Journal of Clinical Oncology|January 2, 2021
Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patientsFeiling Feng, Xiaobing Wu, Xiaoliang Shi, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinomaYuanwen Zheng, Yejun Qin, Wei Gong, et al.
Cancer Research and Treatment|February 15, 2023
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory StudyWeiguang Gu, Hua Zhang, Yiyu Lu, et al.
NPJ Precision Oncology|August 11, 2023
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in ChinaYujun Xu, Xiaoliang Shi, Weifeng Wang, et al.
Nature Communications|January 19, 2026
G9a-mediated H3K9me2 orchestrates intestinal epithelial regeneration through epigenetic silencing of cell cycle-related genesJingzhou Chen, Xiaoliang Shi, Xinyi Zhou, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Oncology Reports|April 3, 2020
Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in non‑small cell lung cancerJing Hu, Yanhong Shang, Xiaoliang Shi, et al.
Frontiers in Oncology|June 27, 2022
A Comprehensive Understanding of the Genomic Bone Tumor Landscape: A Multicenter Prospective StudyXianbiao Xie, Yiying Bian, Haomiao Li, et al.
Translational Oncology|May 6, 2024
The FGF6 amplification mutation plays an important role in the progression and treatment of malignant meningiomaRuihao Liang, Binhua Tan, Kai Lei, et al.
The EMBO Journal|June 9, 2020
Myeloid cells protect intestinal epithelial barrier integrity through the angiogenin/plexin-B2 axisRongpan Bai, Desen Sun, Muxiong Chen, et al.
Scientific Reports|November 21, 2020
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinibYanhong Shang, Xiaofang Li, Weiwei Liu, et al.
International Journal of Clinical Oncology|January 2, 2021
Comprehensive analysis of genomic alterations of Chinese hilar cholangiocarcinoma patientsFeiling Feng, Xiaobing Wu, Xiaoliang Shi, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinomaYuanwen Zheng, Yejun Qin, Wei Gong, et al.
Cancer Research and Treatment|February 15, 2023
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory StudyWeiguang Gu, Hua Zhang, Yiyu Lu, et al.
NPJ Precision Oncology|August 11, 2023
Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in ChinaYujun Xu, Xiaoliang Shi, Weifeng Wang, et al.
Nature Communications|January 19, 2026
G9a-mediated H3K9me2 orchestrates intestinal epithelial regeneration through epigenetic silencing of cell cycle-related genesJingzhou Chen, Xiaoliang Shi, Xinyi Zhou, et al.
Pageof 7